ArticleInfection2026
Epidemic cycles and post-epidemic decline of Mycoplasma pneumoniae in Italian children: implications for empirical macrolide prescribing.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP) circulation has recently re-emerged worldwide, raising concerns about empirical macrolide use in pediatric respiratory infections. We analyzed long-term trends of MP circulation in a tertiary-care pediatric center in Italy between 2017 and 2025. Among 20,539 respiratory molecular tests performed, 648 were positive for MP, with the highest burden observed in children aged 5-12 years. Two epidemic peaks were identified, occurring in 2019 and 2024, followed by a marked and sustained decline in positivity from the last quarter of 2025 onward. Hospitalization was frequent, particularly among patients with underlying comorbidities. Compared with the previous epidemic cycle, the 2024 peak was characterized by higher overall positivity but a lower proportion of hospitalized cases. The sharp post-epidemic reduction in MP circulation underscores the importance of continuous epidemiological surveillance to inform clinical decision-making. These findings support reconsideration of empirical macrolide prescribing during periods of low MP circulation and highlight the role of real-time surveillance data in strengthening antimicrobial stewardship strategies in pediatric care.
Indexed as
Identifiers
42062660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.